Drug profile

The FDA adverse-event record for Amitraz; Metaflumizone

10 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Amitraz; Metaflumizone. See the species affected, top reactions, and outcomes below.

10
adverse-event reports
10.0%
death-coded share
Dog
most-reported species
4
Lack of efficacy (ectoparasite) - Demodex - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
10
Total Reports
1
Deaths Reported
10.0%
Death Rate

Active Ingredients

Amitraz; Metaflumizone

Administration Routes

TopicalOral

Species Affected

Dog 10

Most Affected Breeds

Collie - Border 2
Coonhound - Bluetick 1
Catahoula Leopard Dog 1
Mastiff 1
Deutsche Dogge, Great Dane 1
Terrier - Bull - American Pit 1
Pug 1
Spitz - German Pomeranian 1
Shih Tzu 1

Most Reported Reactions

Lack of efficacy (ectoparasite) - Demodex 4
Skin lesion NOS 3
Other abnormal test result NOS 3
Pruritus 3
Lethargy (see also Central nervous system depression in 'Neurological') 3
Oedema of the extremities (see also other SOCs for most applicable oedema) 2
Erythema (for urticaria see Immune SOC) 2
Pyoderma 2
Hyperphosphataemia 2
Elevated serum alkaline phosphatase (SAP) 2
SKIN SCRAPING ABNORMAL 2
Seizure NOS 2

Outcome Breakdown

Ongoing
8 (80.0%)
Outcome Unknown
1 (10.0%)
Euthanized
1 (10.0%)

Amitraz; Metaflumizone Adverse Event Insights

10 reports name Amitraz; Metaflumizone; 1 recorded a death outcome (10.0% of reported events, not a population-level mortality rate). Active ingredient: Amitraz; Metaflumizone. Administration routes: Topical, Oral.

By species: Dog (10 reports). By breed: Collie - Border (2), Coonhound - Bluetick (1), Catahoula Leopard Dog (1).

Leading clinical signs: Lack of efficacy (ectoparasite) - Demodex (4), Skin lesion NOS (3), Other abnormal test result NOS (3), Pruritus (3). Outcome, 10 coded reports: Ongoing leads at 80.0%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.